Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 143

Sort by

Sort Order Select

Journal Articles

Long Term Survivors (>15 years) of Multiple Myeloma: Patient Characteristics and Morbidity Burden

Rintu Sharma, Karla Alexandra Sanchez, Badraa Muharib, Esther Masih-Khan, Eshetu G. Atenafu, Harjot Vohra, Sita D. Bhella, Christine I Chen, Guido Lancman, Vishal Kukreti, Anca Prica, Donna E Reece, Rodger E Tiedemann, Suzanne Trudel, Chloe Yang, A. Keith Stewart

Blood (2024) 144 (Supplement 1): 7841.

https://doi.org/10.1182/blood-2024-208502

Published: 2024

Journal Articles

Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)

Donna E Reece, Giovanni Piza Rodriguez, Mariela A Pantoja, Eshetu G Atenafu, Darrell White, Irwindeep Sandhu, Julie Stakiw, Michael Sebag, Terrance Comeau, Kevin Song, Jean Roy, Martha L Louzada, Arleigh McCurdy, Vishal Kukreti, Suzanne Trudel, Anca Prica, Rodger E Tiedemann, Christine I Chen

Blood (2024) 144 (Supplement 1): 3376.

https://doi.org/10.1182/blood-2024-206247

Published: 2024

Journal Articles

Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies

Rintu Sharma, Pamella Paul, Esther Masih-Khan, Eshetu G. Atenafu, Harjot Vohra, Sita D. Bhella, Christine I Chen, Vishal Kukreti, Guido Lancman, Donna E Reece, A. Keith Stewart, Rodger E Tiedemann, Chloe Yang, Suzanne Trudel

Blood (2024) 144 (Supplement 1): 1956.

https://doi.org/10.1182/blood-2024-207919

Published: 2024

Journal Articles

Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A Sub-Study of the Cmrg-007 Trial

Martha L Louzada, Donna E. Reece, Arleigh McCurdy, Rami Kotb, Ibraheem Othman, Hira Mian, Toni Lin, Michael P Chu, Darrell White, Stephen Parkin, Engin Gul, Aniba Khan, Suzanne Trudel

Blood (2023) 142 (Supplement 1): 4756.

https://doi.org/10.1182/blood-2023-174993

Published: 2023

Journal Articles

Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10002–10004.

https://doi.org/10.1182/blood-2022-163661

Published: 2022

Journal Articles

Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma

Suzanne Trudel, Arleigh McCurdy, Molei Fu, Heather J. Sutherland, Martha L Louzada, Michael P. Chu, Darrell J White, Hira S Mian, Rami Kotb, Ibraheem Othman, Moustafa Kardjadj, Engin Gul, Donna E. Reece

Blood (2022) 140 (Supplement 1): 7306–7307.

https://doi.org/10.1182/blood-2022-160445

Published: 2022

Journal Articles

Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Blood (2022) 140 (Supplement 1): 289–291.

https://doi.org/10.1182/blood-2022-158219

Published: 2022

Journal Articles

The Canadian Registry for Amyloidosis Research: A National Multi-Disciplinary Registry for Real-World Evidence

Christopher P. Venner, Donna E. Reece, Steven Baker, Vera Bril, Diego Delgado, Mervyn Carr, Geneviève Giraldeau, Victoria Hodgkinson, Victor H Jimenez-Zepeda, Liam A. Laidlaw, Rami Massie, Marsha McWhinnie, Ian Paterson, Nowell Fine, Margot Davis

Blood (2022) 140 (Supplement 1): 13162–13163.

https://doi.org/10.1182/blood-2022-170086

Published: 2022

Journal Articles

Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Anup Joseph Devasia, Sahar Khan, Harminder K Paul, Frédéric Larose, Eshetu G. Atenafu, Donna E. Reece, Suzanne Trudel, A. Keith Stewart, Sita Bhella, Vishal Kukreti, Chloe Yang, Rodger E Tiedemann, Anca Prica, Monica Monchis, Eugene Leung, Susan Jomah, Zubaida Mohamed, Christine Chen

Blood (2022) 140 (Supplement 1): 10043–10044.

https://doi.org/10.1182/blood-2022-170681

Published: 2022

Journal Articles

MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 7289–7291.

https://doi.org/10.1182/blood-2022-159756

Published: 2022

Journal Articles

Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Blood (2022) 140 (Supplement 1): 4287–4289.

https://doi.org/10.1182/blood-2022-168843

Published: 2022

Journal Articles

Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma

Ashish Patel, Adam C. Smith, Esther Masih-Khan, Peace Samuel, Katherine Lajkosz, Sita Bhella, Christine I. Chen, Anca Prica, Donna E. Reece, A. Keith Stewart, Rodger E Tiedemann, Suzanne Trudel, Chloe Yang, Vishal Kukreti

Blood (2022) 140 (Supplement 1): 4354–4355.

https://doi.org/10.1182/blood-2022-167113

Published: 2022

Journal Articles

Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database

Richard Leblanc, Christopher P. Venner, Esther Masih-Khan, Moustafa Kardjadj, Michael P. Chu, Victor H Jimenez-Zepeda, Arleigh McCurdy, Kevin Song, Michael Sebag, Martha L Louzada, Hira S Mian, Darrell J White, Julie Stakiw, Rami Kotb, Anthony Reiman, Muhammad Aslam, Rayan Kaedbey, Engin Gul, Donna E. Reece

Blood (2022) 140 (Supplement 1): 7192–7194.

https://doi.org/10.1182/blood-2022-158679

Published: 2022

Journal Articles

Myeloma Patients with Deletion of 17p: Impact of Tandem Transplant and Clone Size

Alfredo De La Torre, Eshetu G Atenafu, Adam C. Smith, Vishal Kukreti, Anca Prica, Sita Bhella, Donna E. Reece, Rodger E Tiedemann, Suzanne Trudel, Christine I. Chen

Blood (2021) 138 (Supplement 1): 460.

https://doi.org/10.1182/blood-2021-153011

Published: 2021

Journal Articles

Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 161.

https://doi.org/10.1182/blood-2021-148813

Published: 2021

Journal Articles

Supermobilizers with High CD34 + Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma

Eyal Lebel, Katherine Lajkosz, Esther Masih-Khan, Donna E. Reece, Suzanne Trudel, Rodger E Tiedemann, Anca Prica, Vishal Kukreti, Christine I. Chen

Blood (2021) 138 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2021-151862

Published: 2021

Journal Articles

Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

Anca Prica, Vinita Dhir, Rachel Aitken, Harminder K Paul, Osvaldo Espin-Garcia, Sita Bhella, Christine I. Chen, Michael Crump, Robert Kridel, Vishal Kukreti, John Kuruvilla, Donna E. Reece, Rodger E Tiedemann, Suzanne Trudel

Blood (2021) 138 (Supplement 1): 3055.

https://doi.org/10.1182/blood-2021-153120

Published: 2021

Journal Articles

Patient, Caregiver, and Healthcare Provider Priorities for Future Multiple Myeloma Research: Results of a James Lind Alliance Priority Setting Partnership

Anthony Reiman, Samantha Fowler, Lauren McLaughlin, Sarah Bridges, Marc Robichaud, Barbara Ridgway, Donna E. Reece, Kevin W Song, Lorelei Dalrymple, Robin Sully, Sharon Nason, Suzanne Rowland, Trish MacDonald, William Paine

Blood (2021) 138 (Supplement 1): 4984.

https://doi.org/10.1182/blood-2021-145096

Published: 2021

Journal Articles

Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study

Blood (2021) 138 (Supplement 1): 1647.

https://doi.org/10.1182/blood-2021-148723

Published: 2021

Journal Articles

Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Suzanne Trudel, Arleigh McCurdy, Heather J. Sutherland, Martha L Louzada, Christopher P. Venner, Hira S Mian, Rami Kotb, Ibraheem Othman, Fernando Camacho, Engin Gul, Donna E. Reece, Darrell J White, Molei Fu

Blood (2021) 138 (Supplement 1): 1653.

https://doi.org/10.1182/blood-2021-147101

Published: 2021

NARROW

Long Term Survivors (>15 years) of Multiple Myeloma: Patient Characteristics and Morbidity Burden

Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)

Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies

Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A Sub-Study of the Cmrg-007 Trial

Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma

Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma

Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

The Canadian Registry for Amyloidosis Research: A National Multi-Disciplinary Registry for Real-World Evidence

Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation

MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma

Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database

Myeloma Patients with Deletion of 17p: Impact of Tandem Transplant and Clone Size

Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

Supermobilizers with High CD34 + Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma

Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

Patient, Caregiver, and Healthcare Provider Priorities for Future Multiple Myeloma Research: Results of a James Lind Alliance Priority Setting Partnership

Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study

Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only